Endovastec(SH:688016) Sou Hu Cai Jing·2025-12-25 12:25Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase of 1.44% on December 25, 2025, closing at 93.88 yuan, with mixed capital flows indicating a net outflow from major and retail investors, while the stock remains well-positioned in the medical device industry based on key financial metrics [1][3]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main business revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, while the net profit attributable to shareholders was 429 million yuan, a decrease of 22.46% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 300 million yuan, a year-on-year increase of 64.68%, but the net profit attributable to shareholders decreased by 23.63% to 114 million yuan [3]. Capital Flow Analysis - On December 25, 2025, the net outflow of major funds was 1.2198 million yuan, accounting for 1.32% of the total transaction amount, while retail investors saw a net inflow of 4.1196 million yuan, representing 4.46% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net outflows from major and speculative funds on certain days, indicating varying investor sentiment [2]. Industry Positioning - Xinmai Medical's total market capitalization stands at 11.572 billion yuan, with a net asset value of 3.982 billion yuan, and a net profit of 429 million yuan, positioning it favorably compared to the industry averages [3]. - The company has a gross margin of 70.4% and a net margin of 41.69%, ranking it second in the industry for net margin, indicating strong profitability relative to peers [3]. Analyst Ratings - In the last 90 days, eight institutions have provided ratings for Xinmai Medical, with six buy ratings and two hold ratings, and the average target price set at 136.03 yuan [4].